Pfiz­er lines up an $830M al­liance with Arv­inas on pro­tein degra­da­tion

Arv­inas has lined up its third Big Phar­ma part­ner for a trip down the dis­cov­ery path of pro­tein degra­da­tion.

Pfiz­er has signed on to fund the launch of a hunt for a slate of small mol­e­cules that can de­grade pro­teins, a key ther­a­peu­tic path­way that’s been play­ing a role in prostate can­cer and oth­er ar­eas.

Like a lot of Pfiz­er $PFE pacts, the news comes with on­ly a few snip­pets of in­for­ma­tion. We don’t know the up­front, but the over­all pack­et of mile­stones adds up to a whop­ping $830 mil­lion for un­bri­dled suc­cess. To­tal num­ber of pro­grams in­volved? No idea. Dis­ease fo­cus­es? Uh-uh.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN